Melatonin: A new inhibitor agent for cervical cancer treatment

Rana Shafabakhsh, Russel J Reiter, Hamed Mirzaei, Somayyeh Noei Teymoordash, Zatollah Asemi

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Cervical cancer is one of the most common cancers between women and is known as the third leading cause of female cancer related deaths annually. Its detection in early stages allows it to be a preventable and generally treatable disease. Increasing evidence revealed, a variety of internal and external factors are associated with initiation and progression of cervical cancer pathogenesis. Human papilloma virus infection is found as a major cause of cervical cancer. Other molecular and biochemical alterations as well as genetic and epigenetic changes are related cervical cancer progression. Current treatment options often have severe side effects and toxicities thus, new adjuvant agents having synergistic effects and ability to decrease different side effects and toxicities are needed. Melatonin is an indolamine compound secreted from the pineal gland which shows wide range anticancer activities. A large amount of studies indicated inhibitory effects of melatonin against various types of cancers. In addition, experimental evidence reports inhibitory effects of melatonin as an adjuvant therapy on cervical cancer by targeting a sequence of different molecular mechanisms. Herein, for first time, we summarized anticervical cancer effects of melatonin and its underlying molecular mechanisms.

Original languageEnglish (US)
Pages (from-to)21670-21682
Number of pages13
JournalJournal of Cellular Physiology
Volume234
Issue number12
DOIs
StatePublished - Jan 1 2019

Fingerprint

Oncology
Melatonin
Uterine Cervical Neoplasms
Toxicity
Papillomaviridae
Neoplasms
Therapeutics
Viruses
Pineal Gland
Virus Diseases
Epigenomics

Keywords

  • cervical cancer
  • melatonin
  • therapy

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cell Biology

Cite this

Shafabakhsh, R., Reiter, R. J., Mirzaei, H., Teymoordash, S. N., & Asemi, Z. (2019). Melatonin: A new inhibitor agent for cervical cancer treatment. Journal of Cellular Physiology, 234(12), 21670-21682. https://doi.org/10.1002/jcp.28865

Melatonin : A new inhibitor agent for cervical cancer treatment. / Shafabakhsh, Rana; Reiter, Russel J; Mirzaei, Hamed; Teymoordash, Somayyeh Noei; Asemi, Zatollah.

In: Journal of Cellular Physiology, Vol. 234, No. 12, 01.01.2019, p. 21670-21682.

Research output: Contribution to journalReview article

Shafabakhsh, R, Reiter, RJ, Mirzaei, H, Teymoordash, SN & Asemi, Z 2019, 'Melatonin: A new inhibitor agent for cervical cancer treatment', Journal of Cellular Physiology, vol. 234, no. 12, pp. 21670-21682. https://doi.org/10.1002/jcp.28865
Shafabakhsh, Rana ; Reiter, Russel J ; Mirzaei, Hamed ; Teymoordash, Somayyeh Noei ; Asemi, Zatollah. / Melatonin : A new inhibitor agent for cervical cancer treatment. In: Journal of Cellular Physiology. 2019 ; Vol. 234, No. 12. pp. 21670-21682.
@article{2c58af1fcc2d42f8be0b6e6a98a777a3,
title = "Melatonin: A new inhibitor agent for cervical cancer treatment",
abstract = "Cervical cancer is one of the most common cancers between women and is known as the third leading cause of female cancer related deaths annually. Its detection in early stages allows it to be a preventable and generally treatable disease. Increasing evidence revealed, a variety of internal and external factors are associated with initiation and progression of cervical cancer pathogenesis. Human papilloma virus infection is found as a major cause of cervical cancer. Other molecular and biochemical alterations as well as genetic and epigenetic changes are related cervical cancer progression. Current treatment options often have severe side effects and toxicities thus, new adjuvant agents having synergistic effects and ability to decrease different side effects and toxicities are needed. Melatonin is an indolamine compound secreted from the pineal gland which shows wide range anticancer activities. A large amount of studies indicated inhibitory effects of melatonin against various types of cancers. In addition, experimental evidence reports inhibitory effects of melatonin as an adjuvant therapy on cervical cancer by targeting a sequence of different molecular mechanisms. Herein, for first time, we summarized anticervical cancer effects of melatonin and its underlying molecular mechanisms.",
keywords = "cervical cancer, melatonin, therapy",
author = "Rana Shafabakhsh and Reiter, {Russel J} and Hamed Mirzaei and Teymoordash, {Somayyeh Noei} and Zatollah Asemi",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/jcp.28865",
language = "English (US)",
volume = "234",
pages = "21670--21682",
journal = "Journal of Cellular Physiology",
issn = "0021-9541",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - Melatonin

T2 - A new inhibitor agent for cervical cancer treatment

AU - Shafabakhsh, Rana

AU - Reiter, Russel J

AU - Mirzaei, Hamed

AU - Teymoordash, Somayyeh Noei

AU - Asemi, Zatollah

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Cervical cancer is one of the most common cancers between women and is known as the third leading cause of female cancer related deaths annually. Its detection in early stages allows it to be a preventable and generally treatable disease. Increasing evidence revealed, a variety of internal and external factors are associated with initiation and progression of cervical cancer pathogenesis. Human papilloma virus infection is found as a major cause of cervical cancer. Other molecular and biochemical alterations as well as genetic and epigenetic changes are related cervical cancer progression. Current treatment options often have severe side effects and toxicities thus, new adjuvant agents having synergistic effects and ability to decrease different side effects and toxicities are needed. Melatonin is an indolamine compound secreted from the pineal gland which shows wide range anticancer activities. A large amount of studies indicated inhibitory effects of melatonin against various types of cancers. In addition, experimental evidence reports inhibitory effects of melatonin as an adjuvant therapy on cervical cancer by targeting a sequence of different molecular mechanisms. Herein, for first time, we summarized anticervical cancer effects of melatonin and its underlying molecular mechanisms.

AB - Cervical cancer is one of the most common cancers between women and is known as the third leading cause of female cancer related deaths annually. Its detection in early stages allows it to be a preventable and generally treatable disease. Increasing evidence revealed, a variety of internal and external factors are associated with initiation and progression of cervical cancer pathogenesis. Human papilloma virus infection is found as a major cause of cervical cancer. Other molecular and biochemical alterations as well as genetic and epigenetic changes are related cervical cancer progression. Current treatment options often have severe side effects and toxicities thus, new adjuvant agents having synergistic effects and ability to decrease different side effects and toxicities are needed. Melatonin is an indolamine compound secreted from the pineal gland which shows wide range anticancer activities. A large amount of studies indicated inhibitory effects of melatonin against various types of cancers. In addition, experimental evidence reports inhibitory effects of melatonin as an adjuvant therapy on cervical cancer by targeting a sequence of different molecular mechanisms. Herein, for first time, we summarized anticervical cancer effects of melatonin and its underlying molecular mechanisms.

KW - cervical cancer

KW - melatonin

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85068583144&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068583144&partnerID=8YFLogxK

U2 - 10.1002/jcp.28865

DO - 10.1002/jcp.28865

M3 - Review article

C2 - 31131897

AN - SCOPUS:85068583144

VL - 234

SP - 21670

EP - 21682

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 0021-9541

IS - 12

ER -